Collaborations and Other Arrangements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Costs to obtain or fulfill contract capitalized		$ 0
Collaboration revenue		28,935,000	$ 12,606,000
Deferred revenue		55,624,000	49,205,000	$ 60,993,000	$ 63,771,000
Regeneron Pharmaceuticals Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate transaction price remaining to be recognized		41,900,000
Deferred revenue		41,900,000		47,100,000
Development and commercial milestone payments		320,000,000
Regeneron Pharmaceuticals Inc. [Member] | Related Party [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts receivable		35,900,000		35,700,000
Regeneron Pharmaceuticals Inc. [Member] | Hemophilia Co Co Agreements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		3,300,000	2,900,000
Regeneron Pharmaceuticals Inc. [Member] | Regeneron Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		7,400,000	6,800,000
Payments due		4,700,000	4,200,000
Deferred revenue	$ 30,000,000
Collaboration agreement extension period	two years
Collaboration term extension period	2026-04
Sparing Vision [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		500,000	400,000
Deferred revenue		13,700,000		13,900,000
Sparing Vision [Member] | Related Party [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts receivable		300,000		$ 500,000
ReCode Therapeutics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and commercial milestone payments		262,000,000
AvenCell [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		21,000,000	4,900,000
Accounts receivable		$ 200,000
Revenue			4,900,000
Kyverna Therapeutics Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			400,000
ONK Therapeutics [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 100,000